Working... Menu

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002383
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Information provided by:
NIH AIDS Clinical Trials Information Service

Brief Summary:
To compare the antiviral activity, safety, and pharmacokinetics of saquinavir hard gel capsule (HGC) formulation, to 1 of 3 doses of saquinavir soft gel capsule (SGC) formulation administered orally every 8 hours for 4 weeks.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Saquinavir Phase 1

Detailed Description:

Patients are randomly assigned to one of the four treatment groups as follows:

Group 1: 10 patients receive saquinavir HGC. Group 2: 10 patients receive saquinavir SGC. Group 3: 30 patients receive saquinavir SGC at an intermediate dose. Group 4: 30 patients receive saquinavir SGC at the highest study dose. Upon completion of the initial 4 weeks, all patients may have the option to continue their originally-assigned therapy as monotherapy unless significant drug toxicity intervenes. If the analysis of the initial 4 week data identifies an optimal dose of saquinavir SGC, patients may have the option to change to this optimal dose in a treatment extension phase of the protocol. Patients in this extension phase may choose to remain on monotherapy unless they experience significant drug toxicity, their CD4 count or HIV-RNA levels return to baseline, until saquinavir is approved by the FDA or study termination, whichever comes first.

NOTE: A washout >= 28 days is required for patients on antiretroviral therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 80 participants
Primary Purpose: Treatment
Official Title: A Randomized, Parallel, Open-Label Study Comparing Saquinavir (Hard Gelatin Formulation, 600 Mg Tid) to Saquinavir Soft Gelatin Formulation [(400 Mg, 800 Mg, 1200 Mg) Tid} x 4 Weeks in HIV Infected Patients

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Patients must have:

  • CD4 count of 100 to 500 cells/mm3.
  • Greater than 20,000 HIV-RNA copies/ml.

Exclusion Criteria

Prior Medication:


Prior treatment with protease inhibitors.


  • Less than 8 weeks prior antiretroviral treatment (For at least 25% of patients).
  • At least 8 weeks prior antiretroviral treatment (For at least 25% of patients).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00002383

Layout table for location information
United States, Alabama
Univ of Alabama at Birmingham / 1917 Rsch Cln
Birmingham, Alabama, United States, 35294
United States, California
Davis Med Ctr
San Francisco, California, United States, 94114
Mt Zion Hosp of UCSF / HIV Research Ctr
San Francisco, California, United States, 94115
Pacific Oaks Med Group / Research & Scientific Investiga
Sherman Oaks, California, United States, 91403
United States, Louisiana
Tulane Univ Med Ctr / Infectious Diseases Sect
New Orleans, Louisiana, United States, 70112
United States, Massachusetts
New England Med Ctr
Boston, Massachusetts, United States, 02111
United States, Missouri
Kansas City AIDS Research Consortium
Kansas City, Missouri, United States, 64108
United States, New York
Harkness Pavilion
New York, New York, United States, 10032
United States, Oregon
Oregon Health Sciences Univ
Portland, Oregon, United States, 97201
United States, Texas
Univ of Texas Med Branch / Virology Clinic
Galveston, Texas, United States, 775550882
Sponsors and Collaborators
Hoffmann-La Roche

Layout table for additonal information Identifier: NCT00002383     History of Changes
Other Study ID Numbers: 229M
First Posted: August 31, 2001    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: July 1997

Keywords provided by NIH AIDS Clinical Trials Information Service:
Drug Administration Schedule
HIV Protease Inhibitors
Dosage Forms
Anti-HIV Agents

Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors